Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VX-661 plus ivacaftor versus ivacaftor in cystic fibrosis with F508del and an ivacaftor-responsive gating mutation
2014-004838-25Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing VX-661 + ivacaftor with Ivacaftor control (2 arms). Primary endpoint: Absolute change in percent predicted forced expiratory volume in 1 second from baseline. Started Mar 2015; status: completed.
02
Drugs
tezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2014-004838-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004838-25.